Classification criteria for psoriatic arthritis: Development of new criteria from a large international study
2006/07/26 by William Taylor, William J. Taylor, Dafna D. Gladman +6 · 34 citations
Medicine · Immunology and Microbiology · #Spondyloarthritis Studies and Treatments #Rheumatoid Arthritis Research and Therapies #Psoriasis: Treatment and Pathogenesis
paper · doi:10.1002/art.21972
Abstract
OBJECTIVE: To compare the accuracy of existing classification criteria for the diagnosis of psoriatic arthritis (PsA) and to construct new criteria from observed data. METHODS: Data were collected prospectively from consecutive clinic attendees with PsA and other inflammatory arthropathies. Subjects were classified by each of 7 criteria. Sensitivity and specificity were compared using conditional logistic regression analysis. Latent class analysis was used to calculate criteria accuracy in order to confirm the validity of clinical diagnosis as the gold standard definition of "case"-ness. Classification and Regression Trees methodology and logistic regression were used to identify items for new criteria, which were then constructed using a receiver operating characteristic curve. RESULTS: Data were collected on 588 cases and 536 controls with rheumatoid arthritis (n = 384), ankylosing spondylitis (n = 72), undifferentiated arthritis (n = 38), connective tissue disorders (n = 14), and other diseases (n = 28). The specificity of each set of criteria was high. The sensitivity of the Vasey and Espinoza method (0.97) was similar to that of the method of McGonagle et al (0.98) and greater than that of the methods of Bennett (0.44), Moll and Wright (0.91), the European Spondylarthropathy Study Group (0.74), and Gladman et al (0.91). The CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria consisted of established inflammatory articular disease with at least 3 points from the following features: current psoriasis (assigned a score of 2; all other features were assigned a score of 1), a history of psoriasis (unless current psoriasis was present), a family history of psoriasis (unless current psoriasis was present or there was a history of psoriasis), dactylitis, juxtaarticular new bone formation, rheumatoid factor negativity, and nail dystrophy. These criteria were more specific (0.987 versus 0.960) but less sensitive (0.914 versus 0.972) than those of Vasey and Espinoza. CONCLUSION: The CASPAR criteria are simple and highly specific but less sensitive than the Vasey and Espinoza criteria.
Cited by
- The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
- Diagnostic Delay in Psoriatic Arthritis: A Population-based Study
- Central Sensitization in Psoriatic Arthritis: Relationship With Composite Measures of Disease Activity, Functional Disability, and Health-Related Quality of Life
- Correción y calibración de fechas de carbono-14 de los períodos prehistóricos del territorio de Aragón
- The worldwide prevalence of psoriatic arthritis—a systematic review and meta-analysis
- Disease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort
- Imaging in clinical trials for psoriatic arthritis: a scoping review
- Exploring the Genetic Landscape of Psoriatic Arthritis: A Narrative Review of Recent Genomic Studies
- Minimal disease activity and associated factors in patients with psoriatic arthritis: cross-sectional study from a single center
- Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles. [europepmc]
- National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. [europepmc]
- Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. [europepmc]
- Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. [europepmc]
- Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. [europepmc]
- Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. [europepmc]
- The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. [europepmc]
- Epidemiology of spondyloarthritis. [europepmc]
- Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). [europepmc]
- Th17 and Th22 cells in psoriatic arthritis and psoriasis. [europepmc]
- Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? [europepmc]
- Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. [europepmc]
- The Epidemiology of Psoriatic Arthritis. [europepmc]
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. [europepmc]
- International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. [europepmc]
- Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. [europepmc]
- Psoriatic arthritis: state of the art review. [europepmc]
- Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. [europepmc]
- Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. [europepmc]
- Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. [europepmc]
- Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. [europepmc]
- A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. [europepmc]
- Mobile Health Usage, Preferences, Barriers, and eHealth Literacy in Rheumatology: Patient Survey Study. [europepmc]
- Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. [europepmc]
- Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. [europepmc]
Related